WEN LEANA 4/A

What Happened
Wen Leana, a director of Glaukos Corp. (GKOS), was granted 2,987 stock options on May 28, 2026. The award was reported as a derivative grant (acquisition price $0) with an exercise price of $106.52 per share — implying a total exercise cost of about $318,175 if all options are exercised. The options vest in full on the one‑year anniversary of the grant.

Key Details

• Transaction date: May 28, 2026 (Grant / Award, code A)
• Quantity: 2,987 options; Acquisition price reported as $0 (derivative grant)
• Exercise price: $106.52 per share (amended correction; originally misreported as $53.57)
• Vesting: Vests in full one year after grant under the Issuer’s Director Compensation Policy (footnote F2)
• Filing: Amended Form 4 filed June 23, 2026 to correct the exercise price; original Form 4 was filed June 1, 2026 (see footnote F1)
• Post‑transaction holdings: Not specified in the summary — see the Form 4 for total holdings

Context
This was a stock‑option award to a board director (not a market purchase or sale), so it does not represent an immediate cash transaction or disposition. The amendment corrects the strike price; the grant is typical of director compensation and will only have market impact if/when options vest and are exercised or sold.